Events & Presentations Events & Presentations Upcoming Events There are no upcoming events scheduled at this time. Past Events May 18, 2022 KER-012 Investor Call Webcast KER-012 Investor Call Webcast Corporate Presentation KER-012 Investor Call Presentation May 18, 2022 KER-012 Investor Call Presentation 2.5 MB Corporate Presentation March 2022 March 9, 2022 Corporate Presentation March 2022 2 MB KER-050 Investor Call Presentation December 13, 2021 KER-050 Investor Call Presentation 2.2 MB Presentations 2022 ATS International Conference Presentation May 17, 2022 2022 ATS International Conference Presentation 624.3 KB 63rd American Society of Hematology (ASH) Annual Meeting and Exposition December 13, 2021 A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes 1.5 MB RKER-050 Rescued Ruxolinitib (Rux)-induced Reduction in Red Blood Cell Parameters 413.7 KB KER-050, an Inhibitor of TGF-β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in Mouse Model of Disease 666.5 KB A Monoclonal Antibody Targeting ALK2 as a Potential Therapeutic Agent for Anemia of Inflammation 448.3 KB AHA 2021 Scientific Sessions November 15, 2021 AHA 2021 Scientific Sessions 1.7 MB ASBMR 2021 Annual Meeting October 4, 2021 RKER-012, a Novel Activin Receptor Type II Ligand Trap, Protected Rats from PAH Associated Bone Loss in Sugen Hypoxia Model 881.6 KB KER-050 Update June 22, 2021 KER-050 Update 1.1 MB EHA2021 Virtual Congress June 11, 2021 KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB 2021 ATS International Conference Presentation May 14, 2021 2021 ATS International Conference Presentation 646.8 KB European School of Haematology (ESH) 2nd Translational Research E-Conference March 5, 2021 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB ASBMR 2020 Annual Meeting Virtual Event September 11, 2020 KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB 25th European Hematology Association (EHA) Congress (2020) June 12, 2020 Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
Events & Presentations Upcoming Events There are no upcoming events scheduled at this time. Past Events May 18, 2022 KER-012 Investor Call Webcast KER-012 Investor Call Webcast Corporate Presentation KER-012 Investor Call Presentation May 18, 2022 KER-012 Investor Call Presentation 2.5 MB Corporate Presentation March 2022 March 9, 2022 Corporate Presentation March 2022 2 MB KER-050 Investor Call Presentation December 13, 2021 KER-050 Investor Call Presentation 2.2 MB Presentations 2022 ATS International Conference Presentation May 17, 2022 2022 ATS International Conference Presentation 624.3 KB 63rd American Society of Hematology (ASH) Annual Meeting and Exposition December 13, 2021 A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes 1.5 MB RKER-050 Rescued Ruxolinitib (Rux)-induced Reduction in Red Blood Cell Parameters 413.7 KB KER-050, an Inhibitor of TGF-β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in Mouse Model of Disease 666.5 KB A Monoclonal Antibody Targeting ALK2 as a Potential Therapeutic Agent for Anemia of Inflammation 448.3 KB AHA 2021 Scientific Sessions November 15, 2021 AHA 2021 Scientific Sessions 1.7 MB ASBMR 2021 Annual Meeting October 4, 2021 RKER-012, a Novel Activin Receptor Type II Ligand Trap, Protected Rats from PAH Associated Bone Loss in Sugen Hypoxia Model 881.6 KB KER-050 Update June 22, 2021 KER-050 Update 1.1 MB EHA2021 Virtual Congress June 11, 2021 KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB 2021 ATS International Conference Presentation May 14, 2021 2021 ATS International Conference Presentation 646.8 KB European School of Haematology (ESH) 2nd Translational Research E-Conference March 5, 2021 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB 62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB ASBMR 2020 Annual Meeting Virtual Event September 11, 2020 KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB 25th European Hematology Association (EHA) Congress (2020) June 12, 2020 Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
2022 ATS International Conference Presentation May 17, 2022 2022 ATS International Conference Presentation 624.3 KB
63rd American Society of Hematology (ASH) Annual Meeting and Exposition December 13, 2021 A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes 1.5 MB RKER-050 Rescued Ruxolinitib (Rux)-induced Reduction in Red Blood Cell Parameters 413.7 KB KER-050, an Inhibitor of TGF-β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in Mouse Model of Disease 666.5 KB A Monoclonal Antibody Targeting ALK2 as a Potential Therapeutic Agent for Anemia of Inflammation 448.3 KB
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes 1.5 MB RKER-050 Rescued Ruxolinitib (Rux)-induced Reduction in Red Blood Cell Parameters 413.7 KB KER-050, an Inhibitor of TGF-β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in Mouse Model of Disease 666.5 KB A Monoclonal Antibody Targeting ALK2 as a Potential Therapeutic Agent for Anemia of Inflammation 448.3 KB
ASBMR 2021 Annual Meeting October 4, 2021 RKER-012, a Novel Activin Receptor Type II Ligand Trap, Protected Rats from PAH Associated Bone Loss in Sugen Hypoxia Model 881.6 KB
RKER-012, a Novel Activin Receptor Type II Ligand Trap, Protected Rats from PAH Associated Bone Loss in Sugen Hypoxia Model 881.6 KB
EHA2021 Virtual Congress June 11, 2021 KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB
KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis 4.2 MB ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation 1 MB ALK2 inhibition, a novel therapeutic approach to iron overload 1.5 MB Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin 1.2 MB
2021 ATS International Conference Presentation May 14, 2021 2021 ATS International Conference Presentation 646.8 KB
European School of Haematology (ESH) 2nd Translational Research E-Conference March 5, 2021 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB
KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 1.1 MB Targeted ALK2 Inhibition as a Therapeutic Approach to Reducing Hepcidin and Elevating Serum Iron 714.1 KB
62nd American Society of Hematology (ASH) Annual Meeting and Exposition December 7, 2020 KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB
KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production by Promoting Multiple Stages of Erythroid Differentiation 3.1 MB KER-050, a Modified ActRIIA Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies 706 KB Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants 702.1 KB Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron 797.8 KB
ASBMR 2020 Annual Meeting Virtual Event September 11, 2020 KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB
KER-012, a Novel Activin Receptor Type II Ligand Trap Increased Bone in Mice via a Unique Mechanism of Action 1.5 MB
25th European Hematology Association (EHA) Congress (2020) June 12, 2020 Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
